Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence.

ABSTRACT: Adherence monitoring is a vital component of clinical efficacy trials, as the regularity of medication consumption affects both efficacy and adverse effect profiles. Pill-counts do not confirm consumption, and invasive plasma assessments can only assist post hoc assessments. We previously reported on the pharmacokinetics of a potential adherence marker to noninvasively monitor dosage consumption during a trial without breaking a blind. We reported that consumption cessation of subtherapeutic 15 mg acetazolamide (ACZ) doses showed a predictable urinary excretion decay that was quantifiable for an extended period. The current study describes the clinical implementation of 15 mg ACZ doses as an adherence marker excipient in distinct cohorts taking ACZ for different "adherence" durations. We c

SUBMITTER: Hampson AJ 

PROVIDER: S-EPMC7669583 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature